A phase Ib study result of HMPL-689, a PI3K delta inhibitor, in Chinese patients with relapsed/refractory lymphoma

doi:10.1016/j.annonc.2021.08.126

科研成果详情

题名	A phase Ib study result of HMPL-689, a PI3K delta inhibitor, in Chinese patients with relapsed/refractory lymphoma
作者	Cao, J.1; Li, Z.2; Zhou, J.3; Zhang, Q.4; Chen, Y.5; Zhu, Z.6; Li, L.7; Feng, R.8; Li, F.9; Xu, B.10; Yang, W.11; Zhai, Z.12; Zhang, X.13; Wen, Q.14; Xue, H.15; Duan, X.16; Fan, S.16; Cai, Y.16; Su, W.16
会议录名称	ANNALS OF ONCOLOGY 影响因子和分区
语种	英语
原始文献类型	Meeting Abstract
会议名称	Congress of the European-Society-for-Medical-Oncology (ESMO)
会议日期	SEP 16-21, 2021
会议地点	ELECTR NETWORK
资助项目	Hutchison MediPharma Limited
出版地	AMSTERDAM
出版者	ELSEVIER
ISSN	0923-7534
EISSN	1569-8041
卷号	32
页码	S774-S774
DOI	10.1016/j.annonc.2021.08.126
页数	1
WOS类目	Oncology
WOS研究方向	Oncology
WOS记录号	WOS:000700527701292
收录类别	SCIE ; CPCI
发表日期	2021-12-31
自定义期刊分类	T2(B)类
引用统计	被引频次：2[WOS] [WOS记录] [WOS相关记录]
文献类型	会议论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/21879
专题	附属第一医院_血液内科
作者单位	1.Fudan Univ, Dept Oncol, Ctr Canc, Shanghai, Peoples R China; 2.Sun Yat Sen Univ, Dept Oncol, Canc Ctr, Guangzhou, Peoples R China; 3.Huazhong Univ Sci & Technol, Dept Hematol, Tongji Med Coll, Wuhan, Peoples R China; 4.Shanxi Bethune Hosp, Dept Hematol, Taiyuan, Peoples R China; 5.Wenzhou Med Univ, Dept Hematol, Affiliated Hosp 1, Wenzhou, Peoples R China; 6.Henan Prov Peoples Hosp, Dept Hematol, Zhengzhou, Peoples R China; 7.Zhengzhou Univ, Dept Hematol, Affiliated Hosp 1, Zhengzhou, Peoples R China; 8.Southern Med Univ, Dept Hematol, Nanfang Hosp, Guanghzhou, Peoples R China; 9.Nanchang Univ, Dept Hematol, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China; 10.Xiamen Univ, Dept Hematol, Affiliated Hosp 1, Xiamen, Peoples R China; 11.China Med Univ, Dept Hematol, Shengjing Hosp, Shenyang, Peoples R China; 12.Anhui Med Univ, Dept Hematol, Affiliated Hosp 2, Hefei, Peoples R China; 13.Zhejiang Univ, Dept Hematol, Affiliated Hosp 2, Hangzhou, Peoples R China; 14.Peoples Liberat Army Med Univ, Affiliated Hosp 2, Dept Hematol, Chongqing, Peoples R China; 15.Qingdao Univ, Affiliated Hosp, Dept Hematol, Qingdao, Peoples R China; 16.Hutchison MediPharma Ltd, C&R, Bldg 4, Shanghai, Peoples R China
推荐引用方式 GB/T 7714	Cao, J.,Li, Z.,Zhou, J.,et al. A phase Ib study result of HMPL-689, a PI3K delta inhibitor, in Chinese patients with relapsed/refractory lymphoma[C]. AMSTERDAM:ELSEVIER,2021:S774-S774.